Anti-Aging Peptides

For pharmacy compounding, FDA treats GHK-Cu differently by route. On FDA's May 2026 list, GHK-Cu for non-injectable routes is in Category 1, still under evaluation, and FDA plans to consult its advisory committee before the end of February 2027.⁴ Injectable GHK-Cu is on FDA's list of substances whose Category 2 nominations were withdrawn, where FDA notes a possible risk of immune reactions and limited human safety data; that list is not an approval.⁵ Health Canada named GHK-Cu among unauthorized injectable peptides in April 2026.⁶ Here it is sold only for laboratory research under our research use policy.

Its safety in people has not been established: FDA says it has not identified any human exposure data on drug products containing MOTS-c by any route, and lacks important information on whether it would cause harm if given to people.⁵ Health Canada's April 2026 warning about injectable peptides bought online named MOTS-C, and said such products may contain too much, too little or none of the active ingredient, as well as contaminants such as solvents, heavy metals and particles.⁶ The studies that exist are summarized on What is MOTS-c?.

Yes. They are two spellings of one peptide name: FDA and Health Canada write Epitalon, and our catalog lists it as Epithalon.⁵⁶ FDA lists epitalon among substances once in Category 2, its group for significant safety concerns, whose nominations were later withdrawn, and says it has not identified safety information for the proposed route.⁵ Both spellings refer to the Epithalon vial sold here.